USA flag logo/image

An Official Website of the United States Government

Novel Azaborine Derivatives Predicted to Eliminate Acetaminophen Hepatotoxicity

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / STTR
Agency Tracking Number:
R41GM099181
Solicitation Year:
2011
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA10-051
Small Business Information
QUINTESSENCE CHEMICALS, LLC
84851 MCBETH RD EUGENE, OR 97405-9431
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Novel Azaborine Derivatives Predicted to Eliminate Acetaminophen Hepatotoxicity
Agency: HHS
Contract: 1R41GM099181-01
Award Amount: $254,431.00
 

Abstract:

DESCRIPTION (provided by applicant): Overdose on acetaminophen (more commonly known by the brand name Tylenol(R)), accounts for 56,000 emergency room visits and more than 450 deaths annually in the USA. Acetaminophen overdose can occur by a single event ofexceeding the recommended daily dosage. Overdose on acetaminophen is facilitated by the fact that it is a common ingredient in over-the-counter medications for cold, allergies, and congestion, conditions for which people often take multiple medications. The hepatotoxicity of acetaminophen is due to N-acetyl-p- benzoquinoneimine (NAPQI), which is generated by oxidative metabolism. Proposed herein are new 1,2-azaborines, wherein a CC bond pair of an arene is replaced with an isosteric boron- nitrogen unit that is designed to eliminate the formation of the toxic metabolite. This proposal seeks to: 1) synthesize novel 1,2-azaborine-based derivatives of acetaminophen, 2) determine their cytotoxicity and pharmacokinetics via appropriate in vitro tests, and 3) identify compounds to be studied in a Phase II STTR application. PUBLIC HEALTH RELEVANCE: Novel Azaborine Derivatives Predicted to Eliminate Acetaminophen Hepatotoxicity Overdose on acetaminophen (more commonly known by the brand name Tylenol(R)), accounts for 56,000 emergency room visits and more than 450 deaths annually in the USA. The toxicity of acetaminophen to the liver is due to a metabolic by-product. Proposed herein are new boron-nitrogen-containing analogues of acetaminophen that are designedto eliminate the formation of that metabolic by-product.

Principal Investigator:

Shih-yuan Liu
541-346-5573
lsy@uoregon.edu

Business Contact:

Donald Upson
541-913-3921
daupson@yahoo.com
Small Business Information at Submission:

QUINTESSENCE CHEMICALS, LLC
84851 MCBETH RD EUGENE, OR 97405-9431

EIN/Tax ID: 127307610
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF OREGON
5219 UNIVERSITY OF OREGON
EUGENE, OR 97403-5219
Contact: